Pharmacokinetic considerations in the treatment of childhood epilepsy

Pediatric Drugs

Volumn 5, Issue 4, 2003, Pages 267-277

  Gilman, Jamie T ^a   Duchowny, Michael ^b   Campo, Ana E ^c  

^a Neuroscience Clinical Affairs   (United States)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLARITHROMYCIN; CLONAZEPAM; CORTICOSTEROID; CYCLOSPORIN; DEPAKOTE SPRINKLES; DIAZEPAM; ERYTHROMYCIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; MACROLIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SALICYLIC ACID DERIVATIVE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BENIGN CHILDHOOD EPILEPSY; CHILD; DIFFERENTIAL DIAGNOSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FOOD DRUG INTERACTION; HUMAN; LIVER TOXICITY; ORGANOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

EID: 0037266072     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305040-00005     Document Type: Review

References (73)

1. Gottlieb A, Keydor I, Epstein HT. Rodent brain growth stages: an analytical review. Bio Neonate 1977; 32: 166-7
2. Mares P, Trojan S. Ontogenetic development of isonicotine-hydrazide-induced seizures in rats. Brain Dev 1991; 13: 121-5
3. Velisek L, Kubova H, Pohl M, et al. Pentylenetetrazol-induced seizures in rats: an ontogenetic study. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 588-91
4. Zouhar A, Mares P, Liskova-Bernaskova K, et al. Motor and electrocorticographic epileptic activity induced by bicuculline in developing rats. Epilepsia 1989; 30: 501-10
5. Coyle JT, Enna SJ. Neurochemical aspects of the ontogenesis of GABAergic neurons in the rat brain. Brain Res 1976; 111: 119-33
6. Michelson HB, Lothman EW. An in vivo electrophysiologic study of the ontogeny of excitatory and inhibitory processes in rat hippocampus. Brain Res Dev Brain Res 1989; 46: 113-22
7. Swann JW, Brady RJ. Penicillin-induced epileptogenesis in immature rats' CA3 hippocampal pyramidal cells. Brain Res 1984; 12: 243-54
8. Moshe SL, Garant DS. Substantia nigra GABA receptors can mediate anticonvulsant or proconvulsant effects. Epilepsy Res Suppl 1996; 12: 247-56
9. Xu SG, Garant DS, Sperber EF, et al. The proconvulsant effect of nigral infusion of THIP on flurothyl-induced seizures in rat pups. Brain Res Dev Brain Res 1992; 68: 275-7
10. Moshe SL. Seizures in the developing brain. Neurology 1993; 43 Suppl. 5: S3-7
11. Veliskova J, Velisek L, Moshe SL. Age-specific effects of baclofen on pentylenetetrazol-induced seizures in developing rats. Epilepsia 1996; 37 (8): 718-22
12. Lockman LA, Driel R, Zaske D. et al. Phenobarbital dosage for control of neonatal seizures. Neurology 1979; 29: 1445-9
13. Painter MJ, Pippenger C, MacDonald H, et al. Phenobarbital and diphenylhydantoin levels in neonates with seizures. J Pediatr 1978; 92: 315-9
14. Gal P, Toback J, Boer HR, et al. Efficacy of phenobarbital monotherapy in treatment of neonatal seizures in relationship to blood levels. Neurology 1982; 32: 1401-4
15. Gilman JT, Gal P, Duchowny MS, et al. Rapid sequential phenobarbital treatment of neonatal seizures. Pediatrics 1989; 83: 674-8
16. Houghton GW, Richens A, Toseland PA, et al. Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients. Eur J Clin Pharmacol 1975; 9: 73-8
17. Onishi S, Yoshihi O, Nishimura Y, et al. Distribution of phenobarbital in serum, brain and other organs from pediatric patients. Dev Pharmacol Ther 1984; 7: 153-9
18. Painter MJ, Pippenger CE, Wasterlein C, et al. Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology 1981; 31: 1107-12
19. Sherwin AL, Eisen AA, Sokolowski CD. Anticonvulsant drugs in human epileptogenic brain. Arch Neurol 1973; 29: 73-7
20. Gilman JT, Gal P. Pharmacokinetic and pharmacodynamic data collection in children and neonates. Clin Pharmacokinet 1992; 23 (1): 1-9
21. Gilman JT. Developmental principles of antiepileptic drug therapy. J Child Neurol 1994; 9 Suppl. 1: S20-25
22. Gilman JT. Intractable childhood epilepsy: issues in pharmacotherapy. J Epilepsy 1990; 3 Suppl. 1: 21-4
23. Gilman JT. Drug treatment: children. In: Oxbury J, Polkey C, Duchowny M, editors. Intractable focal epilepsy. New York: WB Saunders, 2000: 491-504
24. Radde IC. Mechanisms of drug absorption and their development. In: MacLeod SM, Radde ID, editors. Textbook of pediatric clinical pharmacology. Littleton (MA): PSG Publishing. 1985: 17-43
25. Agunod M, Yonaguchi N, Lopez R, et al. Correlative study of hydrochloric acid, pepsin and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969; 14: 400-14
26. Grand RJ, Watkins JB, Torti FM. Development of the human gastrointestinal tract: a review. Gastroenterology 1976; 70: 400-14
27. Leff RD, Fischer LJ, Roberts RJ. Phenytoin metabolism in infants following intravenous and oral administration. Dev Pharmacol Ther 1986; 9: 217-23
28. Whelan HT, Hendeles L, Haberkern CM, et al. High intravenous phenytoin dosage requirement in a newborn infant. Neurology 1983; 33: 106-8
29. Morselli PL. Development of physiological variables important for drug kinetics. In: Morselli PL, Pippenger CE, Penry JK, editors. Antiepileptic drug therapy in pediatrics. New York: Raven Press, 1983: 1-12
30. Gilman JT, Duchowny MS, Resnick TJ, et al. Carbamazepine malabsorption: a case report. Pediatrics 1988; 82: 518-9
31. Nelson JD, Shelton S, Kusmiesz HT, et al. Absorption of ampicillin and nalidixic acid by infants and children with acute shigellosis. Clin Pharmacol Ther 1972; 13: 879-86
32. Heimann G. Enteral absorption and bioavailability in relation to age. Eur J Clin Pharmacol 1980; 18: 43-50
33. Friis-Hansen B. Body composition during growth: in vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics 1971; 47 Suppl. 2: 264-74
34. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharrnacokinet 1989; 17 Suppl. 1: 29-67
35. Radde IC. Drugs and protein binding. In: MacLeod SM, Radde IC, editors. Textbook of pediatric clinical pharmacology. Littleton (MA): PSG Publishing, 1985: 32-43
36. Brinkschulte M, Breyer-Pfaff V. Increased binding of desmethyl-imipramine in plasma of phenobarbital-treated rats. Biochem Pharmacol 1982; 31: 1749-54
37. Tiula E, Neuvonen PJ. Antiepileptic drugs and alphal-acid glycoprotein [letter]. N Engl J Meal 1982; 3: 1148
38. Riva R, Contin M, Albani F, et al. High alphal-acid glycoprotein concentrations in serum of epileptic children being treated with carbamazepine. Clin Chem 1985; 31: 150-1
39. Bruguerolle B, Jadot G, Bussiere H. Together, phenobarbital and carbamazepine lower alphal-acid glycoprotein concentration in plasma of epileptic patients. Clin Chem 1984; 30: 590-1
40. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimen (part 1). Clin Pharmacokinet 1990; 19: 147-59
41. Albani F, Riva R, Procaaccianti G, et al. Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum. Epilepsia 1983; 24: 65-73
42. Morton LD, Pellock JM, Maria BL, et al. Fosphenytoin safety and pharmacokinetics in children [abstract]. Epilepsia 1997; 38 Suppl. 8: 194
43. Bach B, Hansen JM, Kampmann JP, et al. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981; 6: 389-96
44. Gilman JT. Carbamazepine dosing for pediatric seizure disorders: the highs and lows. Ann Pharmacother 1991; 25: 1109-12
45. Battino D, Bossi L, Croci D, et al. Carbamazepine plasma levels in children and adults: influence of age, dose and associated therapy. Ther Drug Monit 1980; 2: 315-22
46. Hall K, Otten N, Johnston B, et al. A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 1985; 25: 261-8
47. Pynnonen S, Sillanpaa M, Frey H, et al. Carbamazepine and its 10, 11-epoxide in children and adults with epilepsy. Eur J Clin Pharmacol 1977; 11: 129-33
48. Pippenger EC. Maturation of biotransformation rates. In: Morseli PL, Pippenger CE, Penry JK, editors. Antiepileptic drug therapy in pediatrics. New York: Raven Press, 1983: 333-8
49. Cramer JA. Optimizing long-term patient compliance. Neurology 1995; 45 Suppl. 1: S25-28
50. Virani A, Mailis A, Shapiro LE, et al. Drug interactions in human neuropathic pain pharmacotherapy. Pain 1997; 73: 3-13
51. Tatum WO, Gonzalez MA. Carbamazepine toxicity in an epileptic induced by clarithromycin. Hosp Pharm 1994; 29: 45-6
52. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983; 33 (4): 460-4
53. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32: 570-2
54. Krueger KA, Garnett WR, Comstock TJ, et al. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. Epitepsia 1987; 28: 706-12
55. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid - 1988. Clin Pharmacokinet 1988; 15: 367-89
56. Maly MM, Gidal BE, Rutecki P, et al. Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum-concentration ratios [letter]. Epilepsia 1997; 38 Suppl. 8: 101
57. Gilman JT. Perspectiveś on AED interactions. In: Pellock JM, editor. Pediatric epilepsy diagnosis and therapy. 2nd ed. Baltimore (MD): Williams and Wilkins, 2000: 555-8
58. Scarpa P, Carassini B. Partial epilepsy in childhood: clinical and EEG study of 261 cases. Epilepsia 1982; 23: 333-41
59. Resnick TJ. Criteria for surgical evaluation in children with uncontrolled seizures. J Epilepsy 1990; 3 Suppl. 1: 35-40
60. Ramsay ER, Wilder BJ, Berger JR, et al. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983; 33: 904-10
61. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone impartial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-51
62. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-71
63. Chen C, Casale EJ, Duncan B, et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy 1999; 19: 437-41
64. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients (part II). Clin Pharmacokinet 1995; 29: 341-69
65. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients (part I). Clin Pharmacokinet 1995; 29: 257-88
66. Gilman JT, Duchowny M. Childhood epilepsy: current therapeutic recommendations. CNS Drugs 1994; 1: 180-92
67. Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood seizures. Pediatrics 1991; 87: 186-9
68. Shields WD, Lake JL, Chugani HT. Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients. Neurology 1985; 35: 579-81
69. Tada H, Morooka K, Arimoto K, et al. Clinical effects of allopurinol on intractable epilepsy. Epilepsia 1991; 32 (2): 279-83
70. Woody RC. Bromide therapy for pediatric seizure disorder intractable to other antiepileptic drugs. J Child Neurol 1990; 5: 65-7
71. Craig N, Gurbani SG, Miller L, et al. Ketogenic diet: evaluation of its efficacy in children with intractable epilepsy [abstract]. Epilepsia 1997; 38 Suppl. 8: 197
72. Kinsman SL, Vining EPG, Quaskey SA, et al. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992; 33 (6): 1132-6
73. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368-76